321 related articles for article (PubMed ID: 21993387)
1. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA
Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
[TBL] [Abstract][Full Text] [Related]
2. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
3. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.
Lean SY; Ellery P; Ivey L; Thom J; Oostryck R; Leahy M; Baker R; Adams M
Haematologica; 2006 Oct; 91(10):1360-6. PubMed ID: 17018385
[TBL] [Abstract][Full Text] [Related]
4. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.
Adams M; Breckler L; Stevens P; Thom J; Baker R; Oostryck R
Haematologica; 2004 Aug; 89(8):985-90. PubMed ID: 15339683
[TBL] [Abstract][Full Text] [Related]
5. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
[TBL] [Abstract][Full Text] [Related]
6. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.
Amengual O; Atsumi T; Khamashta MA; Hughes GR
Thromb Haemost; 1998 Feb; 79(2):276-81. PubMed ID: 9493575
[TBL] [Abstract][Full Text] [Related]
7. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
[TBL] [Abstract][Full Text] [Related]
8. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies.
Musiał J; Swadźba J; Jankowski M; Grzywacz M; Bazan-Socha S; Szczeklik A
Thromb Haemost; 1997 Oct; 78(4):1173-7. PubMed ID: 9364980
[TBL] [Abstract][Full Text] [Related]
9. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.
Pereira J; Alfaro G; Goycoolea M; Quiroga T; Ocqueteau M; Massardo L; Pérez C; Sáez C; Panes O; Matus V; Mezzano D
Thromb Haemost; 2006 Jan; 95(1):94-9. PubMed ID: 16543967
[TBL] [Abstract][Full Text] [Related]
10. High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa.
Kawakami T; Yamazaki M; Mizoguchi M; Soma Y
Arthritis Rheum; 2007 Dec; 57(8):1507-13. PubMed ID: 18050170
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
13. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.
Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F
Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306
[TBL] [Abstract][Full Text] [Related]
14. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
[TBL] [Abstract][Full Text] [Related]
15. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.
Delgado Alves J; Ames PR; Donohue S; Stanyer L; Nourooz-Zadeh J; Ravirajan C; Isenberg DA
Arthritis Rheum; 2002 Oct; 46(10):2686-94. PubMed ID: 12384928
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
[TBL] [Abstract][Full Text] [Related]
18. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
Eling M; Stephens AC; Oragui EE; Rivers RP; Levin M
Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
